Phase 1Status unknownAge-related condition
Clinical study on the safety and efficacy of allogeneic human bone marrow mesenchymal stem cells in the treatment of sarcopenia-osteoporosis syndrome in the elderly
- Sponsor
- Guangzhou First People's Hospital
- Enrolment
- 25 planned
- Conditions
- Sarcopenia-osteoporosis syndrome; FB83.1Z
- Interventions
- The drug is allogeneic human bone marrow mesenchymal stem cell injection, administered intravenously at a dose of 1×10^8 cells per infusion, once monthly for a total of four doses
- Ages
- adults, older adults
- Registry
- ChiCTR2600129222
Full record on the Chinese Clinical Trial RegistrySource: WHO ICTRP, processed 3 August 2026
Primary outcomes
- The change in bone density compared to the baseline
- The changes in muscle content of the limbs compared to the baseline;
History
Started
Last registry update
Registered